General MedicationsORALGeneric

LEVOMILNACIPRAN HYDROCHLORIDE

Standard Dose

EQ 80MG BASE

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview LEVOMILNACIPRAN HYDROCHLORIDE is listed in Drugs@FDA under application 210826 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LEVOMILNACIPRAN HYDROCHLORIDE Form and strength CAPSULE, EXTENDED RELEASE;ORAL - EQ 80MG BASE Sponsor AUROBINDO PHARMA LTD Submission history Latest submission status date: 2023-01-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview LEVOMILNACIPRAN HYDROCHLORIDE is listed in Drugs@FDA under application 210826 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LEVOMILNACIPRAN HYDROCHLORIDE Form and strength CAPSULE, EXTENDED RELEASE;ORAL - EQ 80MG BASE Sponsor AUROBINDO PHARMA LTD Submission history Latest submission status date: 2023-01-06 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.